Array BioPharma and Amgen Partner in Type 2 Diabetes (Business Wire)
- Monday, December 14, 2009
- Commodities Trading, Featured
- Add a comment
BOULDER, Colo. & THOUSAND OAKS, Calif.—-Array BioPharma Inc. and Amgen Inc. today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.
About the Author
admin has written 4160 stories on this site.
Write a Comment
Gravatars are small images that can show your personality. You can get your gravatar for free today!